Guet-McCreight, Alexandre http://orcid.org/0000-0002-2377-0337
Chameh, Homeira Moradi
Mazza, Frank
Prevot, Thomas D.
Valiante, Taufik A. http://orcid.org/0000-0002-3443-3790
Sibille, Etienne http://orcid.org/0000-0001-5832-6570
Hay, Etay http://orcid.org/0000-0001-8136-6124
Article History
Received: 30 August 2023
Accepted: 9 February 2024
First Online: 23 February 2024
Competing interests
: ES and TP are listed inventors on patents covering syntheses and use of α5-PAM compounds (Title: Treatment of Cognitive and mood systems in Neurodegenerative and Neuropsychiatric disorders with Alpha 5 – containing GABAA selective agonist, US, Canada, EU, JP, Australia, 62/310409; Title: Compositions And Methods Relating To Use Of Agonists Of Alpha5-Containing Gabaa Receptors, US, Canada, EU, JP, Australia, 62/805009; Title: Imidazobenzodiazepines for treatment of cognitive and mood symptoms, US, Canada, EU, JP, Australia, PCT/US2022/042832). EH, ES, and TP are listed inventors and AGM, FM and TAV are listed as collaborators on a patent covering in-silico EEG biomarkers for monitoring α5-PAM treatment efficacy (Title: EEG biomarkers for Alpha5-PAM therapy, United States of America, 63/382,577). ES is the Founder and CSO, and TP is the Director of Operations of Damona Pharmaceuticals, a biopharma dedicated to bringing α5-PAM compounds to the clinic. HMC has no competing interests to declare.